Delayed hepcidin response explains the lag period in iron absorption following a stimulus to increase erythropoiesis

D M Frazer, H R Inglis, S J Wilkins, K N Millard, T M Steele, G D McLaren, A T McKie, C D Vulpe, G J Anderson

Introduction: The delay of several days between an erythropoietic stimulus and the subsequent increase in intestinal iron absorption is commonly believed to represent the time required for body signals to programme the immature crypt enterocytes and for these cells to migrate to the villus. Recent data however suggest that signals from the body to alter absorption are mediated by circulating hepcidin and that this peptide exerts its effect on mature villus enterocytes.

Methods: We have examined the delay in the absorptive response following stimulated erythropoiesis using phenylhydrazine induced haemolysis and correlated this with expression of hepcidin in the liver and iron transporters in the duodenum.

Results: There was a delay of four days following haemolysis before a significant increase in iron absorption was observed. Hepatic hepcidin expression did not decrease until day 3, reaching almost undetectable levels by days 4 and 5. This coincided with the increase in duodenal expression of divalent metal transporter 1, duodenal cytochrome b, and lreg1.

Conclusion: These results suggest that the delayed increase in iron absorption following stimulated erythropoiesis is attributable to a lag in the hepcidin response rather than crypt programming, and are consistent with a direct effect of the hepcidin pathway on mature villus enterocytes.

A ppropriate body iron stores are maintained by regulated absorption of iron by the duodenum as active regulation of iron excretion appears to be limited. However, the mechanism by which body iron requirements signal changes in the intestinal absorption of iron is unclear. One of the most widely accepted theories is that body signals programme duodenal crypt cells to absorb appropriate levels of iron once they have matured and migrated to the villus. Central to this hypothesis is the suggestion that there is a 2–3 day lag period between certain stimuli and the subsequent change in iron absorption. This coincides with the time taken for newly formed cells of the crypts to migrate to the villus tip and, therefore, represents the time required for the absorptive cells of the villus to be completely replaced with newly “programmed” cells from crypts.

We have recently re-evaluated the evidence often quoted in support of a role for crypts in the regulation of iron absorption and found that most studies are more appropriately interpreted as indicating a direct signal from the body to mature enterocytes of the villus. In particular, widely cited papers by Conrad and colleagues and Charlton and colleagues show that an intravenous injection of iron will decrease iron absorption maximally within 18–24 hours, far shorter than the 2–3 day lag period required for programming and migration of crypt cells.

Recent molecular evidence also suggests that signals to alter iron absorption have a direct effect on villus enterocytes. Many of these data have resulted from the discovery of hepcidin, a putative humoral regulator of iron homeostasis. Hepcidin is an antimicrobial peptide produced almost exclusively by the liver and secreted into the bloodstream. Hepatic hepcidin expression is increased in iron overload and decreased in iron deficiency and when erythropoiesis is stimulated. Importantly, mice lacking hepcidin develop severe iron loading whereas mice with constitutively high hepcidin expression develop iron deficiency anaemia. These studies suggest that hepcidin is an inhibitor of iron absorption. We have recently demonstrated that hepcidin expression is decreased in patients with HFE associated haemochromatosis, suggesting that inappropriate hepcidin expression may underlie the increased iron absorption in this disorder. Mutations in hepcidin have also been implicated in the aetiology of severe iron overload in one form of juvenile haemochromatosis. Taken together, these studies suggest that hepcidin is the major signal molecule used by the body to regulate iron absorption in response to changes in body iron requirements.

In addition to regulation by body iron needs, hepcidin is increased during an acute phase response (APR). When an APR is initiated, iron absorption and iron release from the macrophages of the reticuloendothelial (RE) system are decreased, resulting in a reduction in plasma iron concentration. Recent studies have revealed that hypoferraemia accompanying an APR does not occur in mice lacking hepcidin, indicating that the increase in hepcidin in wild-type mice is responsible for decreased absorption. This change in iron absorption occurs within hours rather than days, implying that the signal to alter absorption affects mature villus enterocytes. Indeed, we have previously shown that the increase in hepcidin that occurs during an APR is followed within eight hours by a decrease in duodenal expression of iron transport molecules. In addition, we have shown a close temporal relationship between changes in hepcidin expression and alterations in iron absorption following the switch from an iron replete to an iron deficient diet, suggesting that hepcidin also exerts its effects on...
mature enterocytes during a non-pathogenic response to changes in iron requirements.

The increase in absorption that follows bleeding in both humans and rats however occurs 4–5 days after blood loss.26 This lag period has been interpreted as the time required for the body to programme crypt cells and for these cells to migrate to the villus. Thus one would expect hepcidin expression to decrease several days prior to the change in absorption. We have recently proposed an alternative explanation where the lag period observed after blood loss reflects the time required for the body to detect the need for more iron.4 Thereafter, hepcidin production decreases and there is a rapid increase in iron absorption as hepcidin acts on mature villus enterocytes. According to this scenario, any decrease in hepcidin expression would occur several days after the stimulus to increase erythropoiesis and immediately prior to any increase in absorption.

In the current study, we have examined regulation of iron absorption following increased erythropoiesis accompanying phenylhydrazine (PHZ) induced haemolysis. The studies revealed that the delayed increase in iron absorption is due to a lag in the hepcidin response and that once this occurs, changes in duodenal iron transporter expression and iron absorption rapidly follow. These results support our hypothesis that the hepcidin pathway regulates iron absorption by a direct effect on mature villus enterocytes.

**METHODS**

**Animals and treatment**

Male Sprague-Dawley rats (seven weeks old) were used for all experiments. Rats were allowed unlimited access to a standard pellet diet (Norco Stockfeeds, South Lismore, Australia) and water. To induce haemolysis, rats were administered 100 mg/kg PHZ hydrochloride (ICN Biomedicals Australasia, Seven Hills, Australia) (10 mg/ml in normal saline, pH 7) by intraperitoneal injection. At various time points thereafter, animals were anaesthetised (44 mg/kg ketamine and 8 mg/kg xylazine) and blood was withdrawn from the abdominal aorta for haematological analysis. Total duodenal enterocytes were isolated as previously described22 and snap frozen in liquid nitrogen, as was liver tissue. All experiments described in this study were approved by the Queensland Institute of Medical Research Animal Ethics Committee.

**Assessment of iron absorption, haematological parameters, and liver iron status**

Intestinal iron absorption was measured by whole body counting after oral administration of 59Fe in a duplicate series of animals, as previously described.19 Haemoglobin and haematocrit were measured, as described previously.22 Liver non-haem iron concentration was measured as previously described23 and snap frozen in liquid nitrogen, as was liver tissue. All experiments described in this study were approved by the Queensland Institute of Medical Research Animal Ethics Committee.

**Analysis of serum transferrin species**

The method used to separate the molecular forms of transferrin in serum was based on previous studies.25–27 Briefly, 20× stock buffer (2 M Tris, 0.2 M boric acid, pH 8.4) and urea stock solution (7.5 M, pH 6.0) were deionised using Chelex 100 resin (Bio-Rad Laboratories, Hercules, California, USA) prior to use. Serum was diluted 1 in 9 with rivanol precipitation buffer (3.75 mg/ml rivanol, 10% glycerol in 1× stock buffer) and mixed by inversion. The solution was incubated for 10 minutes at room temperature before being centrifuged at 16 000 g for one minute. Each sample (5 µl) was electrophoresed at 45 V for 17 hours at 4°C. The electrophoretic support medium was a 6 M urea and 6% polyacrylamide gel (37.5:1 acrylamide/bis ratio) prepared in 1× stock buffer. The electrophoresis running buffer was 1× stock buffer containing 1.6 mM EDTA. The protein was then transferred to a membrane and subjected to western blotting, as previously described,26 using a sheep antihuman transferrin primary antibody (Silenus Laboratories, Hawthorne, Australia) diluted 1 in 1000 and an antiserum horseradish peroxidase conjugated secondary antibody (Silenus Laboratories) diluted 1 in 5000.

**RNA extraction and ribonuclease protection assay**

Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Melbourne, Australia) as per the manufacturer’s instructions. Ribonuclease protection assays
(RPAs) were performed as previously described\textsuperscript{19, 28} using 5 µg of total RNA. The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used for normalisation.

**Western blotting and immunohistochemistry**

Protein was extracted from isolated enterocytes and expression of Ireg1 and divalent metal transporter 1 (DMT1) was determined by western blotting, as described previously.\textsuperscript{19, 28} Actin was used as a loading control and was detected using a rabbit antiactin antibody (Sigma-Aldrich). Ireg1 protein was localised by immunofluorescence microscopy using sections cut from duodenal tissue snap frozen in OCT embedding compound (Sakura Finetek USA, Torrance, California, USA), as previously described.\textsuperscript{19} The Ireg1 antibody was used at a 1 in 100 dilution.

**Statistics**

All values are expressed as mean (SEM). Statistical differences between means were calculated using ANOVA followed by Dunnett’s post hoc analysis. Statistical analyses were performed using Instat (GraphPad Software, San Diego, California, USA).

**RESULTS**

**Effect of PHZ induced haemolysis on haematological parameters**

Administration of an intraperitoneal dose of PHZ induced rapid haemolysis with haemoglobin levels and haematocrit decreasing to 48% and 55% of control levels, respectively, after three days (fig 1). These parameters showed a progressive recovery after day 3 with both haemoglobin levels and haematocrit reaching control values by day 6.

The reticulocyte percentage increased dramatically within two days after PHZ treatment, consistent with the expected increase in erythropoiesis, although there was substantial inter-animal variation at this time point (range 20–79%). By day 3, the reticulocyte count had peaked at a mean level 11.6-fold higher than controls. At this time point, the reticulocyte count was consistently elevated in all rats (range 52–60%). Reticulocyte levels declined after day 3 but...
remained significantly higher than control levels seven days after treatment. Examination of transferrin species in the serum of PHZ treated rats by western blotting revealed a distinct decrease in diferric transferrin three days after haemolysis, reaching almost undetectable levels on days 4 and 5 (fig 2). Diferric transferrin then began to recover on days 6 and 7. No major changes in apotransferrin and monoferric transferrin were observed over the course of the experiment.

**Hepatic iron stores and intestinal iron absorption**

Hepatic non-haem iron concentrations increased markedly after PHZ treatment, reaching a maximum 2.3 times that of control animals within three days (fig 3A). Thereafter, liver iron levels appeared to decrease somewhat but remained significantly higher than control levels seven days after haemolysis. Enhanced Perl’s stain of formalin fixed liver sections from day 4 revealed prominent iron deposits, primarily in Kupffer cells (fig 3B). Iron levels were also increased in hepatocytes surrounding portal tracts. No iron deposits were detected in control animals.

To examine the effect of increased erythropoietic activity on intestinal iron absorption, absorption was measured in PHZ treated and control rats. Absorption was significantly increased (3.2-fold compared with controls) four days following injection of PHZ, as shown in fig 4. Absorption remained significantly increased until day 5, then declined to control levels.

**Expression of genes of iron metabolism following PHZ induced haemolysis**

The results described above indicate that our model of stimulated erythropoiesis successfully induced an increase in intestinal iron absorption. Moreover, our results are consistent with the previously reported lag period of approximately four days between the haemolytic stimulus and change in absorption. We next examined whether changes in expression of hepcidin coincided with the change in absorption or whether they preceded the absorption change by several days, as predicted by the crypt programming model. We also examined duodenal expression of genes known or proposed to be involved in iron absorption.

RPA analysis (fig 5) showed that hepcidin mRNA expression was unchanged on the first two days following haemolysis. Thereafter, however, expression decreased dramatically, reaching almost undetectable levels by days 4 and 5. This was followed by a recovery in expression reaching 52% of control levels by day 7. This expression pattern matched closely the observed change in absorption described above. The reduction in hepcidin expression was accompanied by a similarly transient increase in expression of mRNAs encoding the brush border iron transporter DMT1,29 30 the brush border ferrireductase duodenal cytochrome b (Dcytb),31 and the putative basolateral iron transporter Ireg1.32 33 Only the iron responsive element (IRE) containing splice variant of DMT1 is shown, as the non-IRE form is expressed at much lower levels in the gut.28 Similar increases in DMT1 protein were
also observed (Fig 6). Ireg1 protein expression followed the same trend as the other molecules with levels peaking 4–5 days after PHZ induced haemolysis although the difference did not reach statistical significance (Fig 7A). Further examination of Ireg1 protein by immunofluorescence however demonstrated markedly increased expression of the protein on the basolateral surface of duodenal enterocytes four days after PHZ treatment compared with control animals (Fig 7B). Negative controls (without primary antibody) showed no staining (data not shown).

DISCUSSION

The current work confirms and extends the results of previous studies that have demonstrated a lag period of approximately four days after an erythropoietic stimulus before intestinal iron absorption increases. This delay is proposed to represent the time taken for immature enterocytes of the crypts to receive signals from the body and then migrate to the villus and differentiate into absorptive cells. However, recent molecular studies have provided evidence that signals to alter iron absorption are mediated by hepcidin and have a direct effect on mature enterocytes (for review, see Frazer and Anderson). The delay in absorption following stimulated erythropoiesis is still consistent with such a direct action if the delay represents the time required by the body to detect the need for more iron and alter hepcidin expression. The studies described in this paper were conducted to investigate this possibility by using PHZ induced haemolysis to stimulate erythropoiesis in a rat model.

We observed no change in expression of hepcidin until three days after administration of PHZ, with the lowest levels evident 4–5 days after haemolysis was induced. This coincided with the highest levels of absorption and with peak expression of molecules involved in intestinal iron transport. The close temporal relationship between changes in hepcidin expression and changes in intestinal iron absorption is consistent with the concept that the lag period following a stimulus to increase erythropoiesis represents the time required for the body to assess iron needs. Once the requirement for more iron is recognised, hepcidin expression is decreased, resulting in a rapid increase in iron transporter expression and hence iron absorption. This sequence of
The results of the current study agree with our previous data showing that changes in hepcidin expression are closely associated with changes in iron transporter expression and iron absorption. This was the case following both the change from a control to an iron deficient diet and after induction of an APR. In the latter investigation, we found that DMT1 expression was reduced by both physiological and pharmacological means. The decrease in DMT1 expression resulted in an increase in iron stores and a subsequent increase in iron absorption. This was the case following both the change from a control to an iron deficient diet and after induction of an APR. In the latter investigation, we found that DMT1 and Dcytb expression decreased within eight hours of an increase in hepcidin. In the current study, this model provides support for the hypothesis that hepcidin acts to increase or decrease absorption via an effect on villus enterocytes. It is interesting to note that, in the current study, we observed only small increases in levels of Ireg1 mRNA and protein but a significant increase in the amount of Ireg1 on the basolateral membrane, supporting previous suggestions that post-translational events are important in the regulation of Ireg1 mediated iron export. In addition to changes in transporter expression, it has previously been demonstrated that changes in membrane potential and villus length in the duodenum accompany PHZ induced haemolysis and such changes could also contribute to the observed increase in iron absorption.

It has been shown that expression of hepcidin is influenced by both body iron stores and the rate of erythropoiesis but it is not known how the body detects the need for more iron and regulates hepcidin expression accordingly. The existence of a “stores regulator” has been proposed as a mechanism that is responsive to the body’s iron stores, increasing absorption when stores are low and decreasing absorption when the body is iron replete. Similarly, a proposed “erythroid regulator” appears to adjust iron absorption in response to the iron requirements of the bone marrow, functioning to ensure that an adequate supply of iron is maintained for erythropoiesis by increasing iron absorption when the body is iron replete. In this model, increased transthyretin (TTR) levels in the body were shown to stimulate iron release from the reticuloendothelial system (RES) and increase iron absorption. The increase in TTR levels per se has been shown to increase iron absorption, as in patients with hepcidin mutations both transferrin saturation and intestinal absorption are greatly elevated. An intriguing observation in the current study is the return of iron absorption to normal by day 7 following PHZ treatment, despite incomplete recovery of hepcidin expression. The fact that reticulocyte counts remained high at this time suggests that erythropoiesis, and hence iron demand, was still elevated in these animals, albeit not to the same extent seen at 3–4 days after PHZ treatment. A likely explanation for this phenomenon is the continued presence of an increased number of erythroid precursors still maturing in the marrow, following the initial expansion of the erythroid mass in response to the episode of haemolysis one week earlier. This is consistent with intermediate hepcidin levels seen on day 7. Persistence of reticulocytosis despite a return of absorption to normal implies that RES iron output remains increased at a level that is adequate to satisfy the increased erythropoietic demand. Thus it appears that small to modest reductions in hepcidin levels are sufficient to stimulate iron release from the RES system but that stimulation of intestinal iron absorption requires a further decrease until levels fall below a certain threshold. Such differential regulation would allow the body to modulate iron output from RES cells in response to alterations in body iron demand (particularly iron supply to the erythroid marrow) without invoking changes in absorption so that more iron can be made available without increasing total body iron load. This may explain the fact that haemolytic anaemias in which erythropoiesis remains effective (for example, chronic haemolytic states such as hereditary spherocytosis) are not typically accompanied by increased iron absorption and do not usually lead to iron overload. However, in haemolytic conditions associated with increased ineffective erythropoiesis, such as β-thalassaemia, the increased RES system output cannot adequately supply iron to the greatly expanded erythroid mass and absorption increases as a result. One would predict that hepcidin expression would be lower in the latter case. This is supported by recent evidence demonstrating that thalassaemic mice express lower than expected levels of hepcidin.

In conclusion, the current study supports the proposal that the hepcidin pathway exerts a direct effect on the mature villus enterocytes of the duodenum and suggests that the time lag between a stimulus to increase erythropoiesis and the subsequent increase in iron absorption represents the time required by the body to detect the need for more iron. In the case of haemolytic anaemia, this represents the time between the onset of anaemia and the ensuing increase in erythropoiesis. Once the increased need for iron has been recognised, there is a decrease in hepatic hepcidin expression, followed rapidly by an increase in iron absorption. The decrease in hepcidin expression observed in this study occurred shortly after the onset of increased iron demand by the marrow, supporting our proposal that the amount of plasma diferric transferrin plays a central role in the regulation of body iron homeostasis.
ACKNOWLEDGEMENTS
This work was supported in part by grants from the National Health and Medical Research Council of Australia, the National Institute of Diabetes and Digestive and Kidney Diseases (801 DK-37808), and the Human Frontier Science Program (RGY0328/2001-M).

Authors’ affiliations
D M Frazer*, H R Ingles*, S J Wilkins, K N Millard, T M Steele, G J Anderson, Ion Metabolism Laboratory, the Queensland Institute of Medical Research and the University of Queensland, PO Royal Brisbane Hospital, Brisbane, Queensland, Australia
G D McLaren, Division of Haematology/Oncology, University of California, Irvine, Irvine, California, USA, and VA Long Beach Healthcare System, Long Beach, California, USA
A T McKie, Division of Life Sciences, King’s College, London, UK
C D Vulpe, Department of Nutritional Sciences and Toxicology, University of California, Berkeley, California, USA

*D M Frazer and H R Ingles contributed equally to the manuscript.

REFERENCES
Delayed hepcidin response explains the lag period in iron absorption following a stimulus to increase erythropoiesis

D M Frazer, H R Inglis, S J Wilkins, K N Millard, T M Steele, G D McLaren, A T McKie, C D Vulpe and G J Anderson

Gut 2004 53: 1509-1515
doi: 10.1136/gut.2003.037416

Updated information and services can be found at:
http://gut.bmj.com/content/53/10/1509

These include:

References
This article cites 40 articles, 14 of which you can access for free at:
http://gut.bmj.com/content/53/10/1509#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/